The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vidalain, P.-O.
Right arrow Articles by Servet-Delprat, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vidalain, P.-O.
Right arrow Articles by Servet-Delprat, C.
The Journal of Immunology, 2001, 167: 3765-3772.
Copyright © 2001 by The American Association of Immunologists

Cytotoxic Activity of Human Dendritic Cells Is Differentially Regulated by Double-Stranded RNA and CD40 Ligand1

Pierre-Olivier Vidalain*, Olga Azocar*, Hideo Yagita{dagger}, Chantal Rabourdin-Combe* and Christine Servet-Delprat2,*

* Laboratoire d’Immunobiologie Fondamentale et Clinique, Institut National de la Santé et de la Recherche Médicale Unité 503, Lyon, France; and {dagger} Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The main function of dendritic cells (DCs) is to induce adaptive immune response through Ag presentation and specific T lymphocyte activation. However, IFN-{alpha}- or IFN-{gamma}-stimulated CD11c+ blood DCs and IFN-{beta}-stimulated monocyte-derived DCs were recently reported to express functional TNF-related apoptosis-inducing ligand (TRAIL), suggesting that DCs may become cytotoxic effector cells of innate immunity upon appropriate stimulation. In this study, we investigate whether dsRNA and CD40 ligand (CD40L), that were characterized as potent inducers of DC maturation, could also stimulate or modulate DC cytotoxicity toward tumoral cells. We observed that dsRNA, but not CD40L, is a potent inducer of TRAIL expression in human monocyte-derived DCs. As revealed by cytotoxicity assays, DCs acquire the ability to kill tumoral cells via the TRAIL pathway when treated with dsRNA. More precisely, dsRNA is shown to induce IFN-{beta} synthesis that consecutively mediates TRAIL expression by the DCs. In contrast, we demonstrate that TRAIL expression in dsRNA- or IFN-{alpha}-treated DCs is potently inhibited after CD40L stimulation. Unexpectedly, CD40L-activated DCs still developed cytotoxicity toward tumoral cells. This latter appeared to be partly mediated by TNF-{alpha} induction and a yet unidentified pathway. Altogether, these results demonstrate that dsRNA and CD40L, that were originally characterized as maturation signals for DCs, also stimulate their cytotoxicity that is mediated through TRAIL-dependent or -independent mechanisms.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Dendritic cells (DCs)3 are considered as sentinels of the immune system (1). Immature DCs reside in peripheral tissues, where they survey incoming pathogens. The capacity of DCs to recognize pathogens and become activated therefore represents the first critical event in the initiation of the immune response. Because of the wide variety of pathogens, DCs are equipped with receptors to become activated when exposed to pathogen-associated molecular patterns (PAMPs) (2) such as LPS (3) or CpG motif in DNA from bacteria (4). Encounter with pathogen leads to DC maturation and migration to secondary lymphoid organs. Ag presentation by DCs activates specific naive T cells to express CD40 ligand (CD40L) (5), which, in turn, activates DCs, achieving the terminal differentiation required to develop adaptive immunity (6, 7). Indeed, signaling through CD40 leads to up-regulation of MHC I and II molecules, CD80/CD86 and cytokines such as IL-12 and IL-1{alpha}{beta}, which all participate in T cell stimulation (6, 8, 9).

DC effector function may not be restricted to Ag presentation. Indeed, recent reports demonstrate that human CD11c+ blood DCs, upon IFN -{alpha} or IFN-{gamma} stimulation (10), and monocyte-derived DCs, upon IFN-{beta} stimulation or measles virus infection (11, 12), acquire the ability to kill tumoral cells. In these cases, cytotoxic activity of DCs was TNF-related apoptosis inducing ligand (TRAIL) mediated. TRAIL is a type II membrane protein of the TNF family closely related to three death-inducing ligands: FasL, TNF-{alpha}, and TWEAK/Apo3L (13, 14). TRAIL induces apoptosis by cross-linking death domain-containing receptors TRAIL-R1 (also known as DR4) (15) or TRAIL-R2 (also called DR5 or KILLER/DR5 or TRICK2) (16, 17, 18, 19, 20). Apoptotic signaling occurs by recruitment of Fas-associated death domain adapter protein that later on induces caspase 8 activation (21, 22). Among the molecule known to induce apoptotic cell death, TRAIL has received great attention because of its potential therapeutic applications. Indeed, it was reported that TRAIL specifically induces apoptosis in virus-infected cells (23, 24) and tumoral cells (13, 14, 25, 26, 27) with minimal cytotoxicity toward normal tissues in vivo (28). These results suggest that TRAIL-expressing DCs may operate in vivo like innate effector cells that induce virus-infected and tumoral cell apoptosis. More recently, TRAIL was also described as a potent inhibitor of autoimmune arthritis and inflammation. Indeed, TRAIL inhibits activated T cell proliferation and cytokine production (29, 30). These last results demonstrate that not only TRAIL may be an innate immunity effector molecule involved in the elimination of virus-infected or tumoral cells, but also it may play an inhibitory role in adaptive immunity through limiting T cell activation. Consequently, the stimulatory capacity of TRAIL-expressing DCs is questionable as TRAIL might inhibit T cell activation.

dsRNA is a common by-product of RNA virus replication that signals to the immune system and activates antiviral immune response (31). In this study, DCs were stimulated with poly(I:C) that is a synthetic dsRNA often used in models of viral infection. Poly(I:C) was recently reported to induce maturation in DCs, suggesting that dsRNA behaves as a structural signature of viruses that can directly signal to DCs the presence of an infectious pathogen (32, 33, 34). In contrast to dsRNA, CD40L is a basic endogenous signal that ensures the initiation of adaptive immune responses through the induction of full DC maturation.

In this study, dsRNA and CD40L were tested for their ability to stimulate innate DC cytotoxicity toward tumoral cells. We demonstrate that human monocyte-derived DCs developed TRAIL-mediated cytotoxic activity toward tumoral cells after stimulation with dsRNA. TRAIL induction is shown to be dependent on the expression of IFN-{beta} by the DCs. Contrary to dsRNA, CD40L stimulation was shown to inhibit TRAIL expression in DCs. Unexpectedly, CD40L-activated DCs still developed cytotoxic activity toward tumoral cells. This latter did appear to be partly mediated by TNF-{alpha} induction and a yet unidentified pathway. Altogether, these results demonstrate that dsRNA and CD40L that were originally characterized as DC maturation signals, also stimulate DC cytotoxicity.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Reagents

dsRNA was poly(I:C) and ssRNA was poly(C) obtained from Amersham Pharmacia Biotech (Piscataway, NJ; recombinant human (rh) IFN-{alpha}A and rhIFN-{beta} were purchased from Calbiochem (La Jolla, CA); rhTNF-{alpha} was kindly provided by the Schering-Plough Laboratory for Immunological Research (Dardilly, France); sheep polyclonal anti-human IFN-{alpha} and sheep polyclonal anti-human IFN-{beta} Abs were purchased from BioSource International (Camarillo, CA); CD1a-PE, CD14-PE, HLA-DR-FITC, CD80-PE, CD83-PE, CD86-PE, and CD25-PE Abs were obtained from Immunotech (Marseille, France); anti-human CD40L (mAb LL2) was generously provided by the Schering-Plough Laboratory for Immunological Research.

Cells

Monocyte-derived DCs were generated in vitro as previously described (35). After 6 days of culture in the presence of 50 ng/ml rhGM-CSF (kindly provided by Schering-Plough) and 500 U/ml rhIL-4 (TEBU, Le Perray en-Yvelines, France), >95% of the cells were DCs as assessed by CD1a labeling. Cultures of DCs were performed in RPMI 1640 (Life Technologies, Paisley, U.K.) supplemented with 10 mM HEPES (Life Technologies), 2 mM L-glutamine (Life Technologies), 40 µg/ml gentamicin (Life Technologies), and 10% FCS (Boehringer Mannheim, Meylan, France). DCs were cultured at 106 cells/ml. In the murine fibroblast cocultures, 106 DCs/ml were cultured in the presence of 105/ml irradiated (7000 rad) fibroblastic CD40L- or CD32-transfected L cells (both kindly provided by Schering-Plough Laboratory for Immunological Research). Murine 2PK-3 lymphoma and human TRAIL-transfected 2PK-3 were previously characterized (36).

Phenotypic analysis

Immunostainings were performed in 1% BSA and 3% human serum-PBS. To perform cytoplasmic TRAIL and TNF-{alpha} immunostainings, 30-min permeabilization with 0.33% saponin was required. For TRAIL detection, cells were labeled by using a biotin-conjugated anti-TRAIL polyclonal Ab (2.5 µg/ml; R&D Systems, Minneapolis, MN) revealed by using PE-conjugated streptavidin (Caltag Laboratories, Burlingame, CA). For TNF-{alpha} detection, cells were labeled by using anti-TNF-{alpha} mAb (10 µg/ml; R&D Systems) revealed by using antimouse PE-conjugated Ab (Immunotech).

Type I IFN detection

At 24 h, supernatants were collected for type I IFN detection. The supernatants were serially diluted 2-fold in a 96-microwell plate and added to confluent vero monolayer cells in RPMI 1640 plus 5% FCS. After incubation for 24 h at 37°C, the cells were infected with vesicular stomatitis virus at 0.1 PFU/cell. Cytopathic effects were scored under the microscope 24 h later. Titration end point represents dilutions that gave destruction of 50% of the cells. IFN titers are expressed as International Units per milliliter with reference to a standard IFN curve. IFN-{alpha} and IFN-{beta} levels in the DC supernatants were determined by ELISA following the manufacturer’s specification (R&D Systems).

Cytotoxicity assay

To determine cytotoxic activity of DCs, TRAIL-sensitive MDA231 cells were labeled with 100 µCi of 51Cr for 1 h at 37°C, washed three times, and resuspended in complete medium. Then 51Cr-labeled MDA231 cells (104/well) were incubated with varying numbers of effector cells for 8 h. Anti-TNF-{alpha} mAb (10 µg/ml; R&D Systems), anti-TRAIL RIK-2 mAb (10 µg/ml; Ref. 36) or anti-TWEAK/Apo3L CARL-1 Ab (10 µg/ml; Ref. 37) were added to some assays.

RNase protection assays

RNA was extracted from 4 x 106 cells using RNA NOW-TC reagent (Biogentex, Seabrook, TX). The RNase protection was performed using 4 µg of RNA with the RiboQuant multiprobe RNase assay system (BD PharMingen, San Diego, CA) according to the manufacturer’s specification. In brief, RNA was hybridized overnight with the in vitro-translated 32P-labeled probe (hAPO-3c; BD PharMingen). Following hybridization, samples were treated with RNase A+T1 and proteinase K, phenol-chloroform extracted, and ethanol precipitated. The protected fragments were resolved by electrophoresis on a 5% acrylamide/urea gel and exposed on a Phosphor Screen (Molecular Dynamics, Sunnyvale, CA) for 12 h to quantify the intensity of the bands.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
dsRNA induces TRAIL production in monocyte-derived DCs

DCs were obtained from purified blood monocytes cultured for 6 days in the presence of GM-CSF and IL-4. These cells expressed high levels of CD1a and HLA-DR but did not express the monocyte marker CD14, indicating that they were fully differentiated DCs (Fig. 1GoA). Then DCs were cultured with a dose response of dsRNA (poly I:C) concentration for 12 h. As dsRNA was previously described to induce DC maturation (32, 33), expression of CD80 and CD86 costimulatory molecules and CD83 and CD25 maturation markers was quantified. As shown in Fig. 1GoB, initiation of DC maturation was observed following stimulation with 0.2 µg/ml dsRNA but higher concentration of 20 µg/ml was required to induce full phenotypic DC maturation. IFN-{alpha} and CD40L stimulation were used as a negative and positive control for DC maturation, respectively. Then TRAIL expression was quantified by flow cytometry analysis. Surface TRAIL expression was bright positive in dsRNA-treated monocytes (Fig. 2GoA). In the same culture conditions, surface TRAIL expression in DCs was very weak. However, intracellular stainings revealed a strong induction of cytoplasmic TRAIL in DCs treated with dsRNA (Fig. 2GoC), suggesting that most of TRAIL in DCs was cleaved by a specific protease when expressed on the cell surface. The specificity of this intracellular immunostaining was confirmed by using untransfected or human TRAIL-transfected 2PK-3 cells as negative and positive controls, respectively (Fig. 2GoB). In contrast to dsRNA, ssRNA poly(C) had no effect on TRAIL expression. Maximal TRAIL induction was observed following stimulation with low dsRNA concentration (0.2 µg/ml; Fig. 2GoD). Thus, DCs were hypersensitive to dsRNA as the concentration required to induce TRAIL is 100 times lower than the concentration required for full phenotypic DC maturation. Contrary to dsRNA, CD40L had no effect on TRAIL expression (Fig. 2Go, C and D). This observation demonstrates that DC maturation by itself does not induce TRAIL expression.



View larger version (32K):
[in this window]
[in a new window]
  		FIGURE 1. Phenotype of monocyte-derived DCs stimulated with dsRNA, IFN-{alpha}, or CD40L. A, CD1a, CD14, and HLA-DR expressions in day 6 monocyte-derived DCs were quantified by flow cytometry analysis. B, Monocyte-derived DCs were left unstimulated or cultured for 16 h in the presence of different doses of dsRNA or rhIFN-{alpha} (5000 U/ml) or CD40L+ L cells (L cells:DCs ratio, 1:7). CD80, CD86, CD83, and CD25 expression was quantified by flow cytometry. Data shown are from one representative experiment of three.

 


View larger version (28K):
[in this window]
[in a new window]
  		FIGURE 2. TRAIL expression in DCs stimulated with dsRNA poly(I:C), ssRNA poly(C), IFN-{alpha}, IFN-{beta}, or CD40L. A, Monocytes or DCs were cultured for 16 h in the presence or absence of dsRNA (0.2 µg/ml) or IFN-{alpha} (5000 U/ml). Surface TRAIL expression was quantified by FACS. Cells were stained with an isotypic control (thin line) or an anti-TRAIL Ab (heavy line). Data shown are FACS histograms from one representative experiment of four. B, FACS histograms of TRAIL immunostainings performed on permeabilized human TRAIL-transfected or untransfected 2PK-3 cells. C and D, DCs were cultured for 16 h in the presence or absence of CD40L+ L cells (L cells:DCs ratio, 1:7), ssRNA poly(C) (0.2 µg/ml), dsRNA poly(I:C) (0.2 µg/ml if not precised), IFN-{alpha} (5000 U/ml), or IFN-{beta} (500 U/ml). Cytoplasmic TRAIL expression was quantified by flow cytometry. Cells were permeabilized and then stained with an isotypic control (thin line) or an anti-TRAIL Ab (heavy line). C, FACS histograms of TRAIL immunostaining on DCs. Data shown are from one representative experiment of five. D, Percentage of TRAIL-positive DCs. Data shown are means ± SD of five independent experiments.

 
dsRNA-induced TRAIL synthesis is dependent on IFN-{beta} production

Up-regulation of TRAIL was observed following rIFN-{alpha} or IFN-{beta} stimulation of DCs (Fig. 2GoC). Because dsRNA was reported to induce type I IFNs in DCs (32, 34), the question of their involvement in TRAIL induction was addressed. First, type I IFN induction by dsRNA was confirmed by using a biologic titration assay (Table IGo). Second, IFN-{alpha} and IFN-{beta} concentrations in DC supernatants were determined by ELISA. As shown in Table IGo, IFN-{beta} but not IFN-{alpha} was produced by dsRNA-stimulated DCs. This led us to demonstrate that IFN-{beta} was responsible for TRAIL induction by dsRNA. DCs were stimulated with 0.2 µg/ml dsRNA in the presence of anti-IFN-{alpha} or anti-IFN-{beta} or a combination of both Abs. As shown in Fig. 3Go, anti-IFN-{beta} or a combination of anti-IFN-{alpha} and anti-IFN-{beta} Abs abrogated TRAIL induction in DCs. In contrast, anti-IFN-{alpha} Ab alone had no effect on TRAIL expression by dsRNA-stimulated DCs. In conclusion, TRAIL induction in DCs following dsRNA stimulation is dependent on autocrine/paracrine IFN-{beta} synthesis.


View this table:
[in this window]
[in a new window]
  		Table I. Type I IFN expression in DCs with or without dsRNA1

 


View larger version (32K):
[in this window]
[in a new window]
  		FIGURE 3. Involvement of type I IFNs in dsRNA-induced TRAIL expression by DCs. DCs stimulated with 0.2 µg/ml dsRNA were cultured for 16 h in the presence of neutralizing anti-IFN-{alpha} or anti-IFN-{beta} Abs or a combination of both (2000 neutralizing U/ml anti-IFN-{alpha} and 500 neutralizing U/ml anti-IFN-{beta}). Permeabilized DCs were stained with an isotypic control (thin lines) or an anti-TRAIL Ab (heavy lines). Data shown are from one representative experiment of three.

 
dsRNA-stimulated DCs exert TRAIL-mediated cytotoxicity

Cytotoxic activity of dsRNA-stimulated DCs was tested on TRAIL-sensitive human breast adenocarcinoma MDA231 (Fig. 4Go). Unstimulated DCs did not exhibit cytotoxic activity against MDA231 cells. When stimulated for 16 h with 0.2 µg/ml dsRNA, DCs induced MDA231 cell lysis (Fig. 4GoA). In our assay, cytotoxicity of dsRNA-stimulated DCs was comparable, in terms of intensity, to cytotoxicity of either IFN-{alpha}- or IFN-{beta}-stimulated DCs (Fig. 4GoA). As a positive control, human TRAIL-transfected 2PK-3 cells were shown to induce 30–40% MDA231-specific lysis (data not shown). We next examined the contribution of TRAIL in the cytotoxicity of dsRNA-stimulated DCs. As shown in Fig. 4GoB, target cell lysis was strongly inhibited by neutralizing anti-TRAIL Ab (RIK-2). In contrast, neither anti-TWEAK/Apo3L- nor anti-TNF-{alpha}-neutralizing Abs inhibited cytotoxicity of dsRNA-stimulated DCs. Thus, we conclude that TRAIL is responsible for cytotoxicity of dsRNA-stimulated DCs.



View larger version (17K):
[in this window]
[in a new window]
  		FIGURE 4. dsRNA-induced TRAIL synthesis is responsible for DC cytotoxicity. A, DCs were stimulated or not with dsRNA (0.2 µg/ml) or IFN-{alpha} (5000 U/ml) or IFN-{beta} (500 U/ml) for 16 h. Cytotoxicity was then tested against MDA231 cells by an 8-h 51Cr release assay at different E:T ratios. B, DCs were stimulated with dsRNA (0.2 µg/ml). Neutralizing anti-TRAIL (RIK-2) or anti-TNF-{alpha} or anti-TWEAK/Apo3L (CARL-1) Abs was added or not in the assay to inhibit TRAIL- or TNF-{alpha}- or TWEAK/Apo3L-induced lysis. Data represent the mean of triplicate samples (SD below 5%). Data shown are from one representative experiment of five.

 
CD40 engagement inhibits TRAIL but induces TNF-{alpha} expression in DCs

TRAIL was recently described to prevent cell cycle progression of T lymphocyte and cytokine production (29, 30). Consequently, inhibition of TRAIL expression is essential in DCs as it might interfere with their APC function. To test whether CD40L inhibits TRAIL expression, DCs were stimulated with IFN-{alpha} or dsRNA (0.2 µg/ml) and cultured in the presence of control L cells or CD40L+ L cells. Addition of CD40L+ L cells in the culture inhibited TRAIL mRNA expression induced by IFN-{alpha} or dsRNA, whereas control L cells did not (Fig. 5GoA). FasL mRNA expression was never detected in any of the culture conditions tested. At the protein level, CD40L+ L cells also inhibited TRAIL expression in DCs. This effect was exclusively dependent on CD40L as TRAIL inhibition was blocked by neutralizing anti-CD40L Abs. Control L cells did not affect TRAIL expression (Fig. 5GoB). These results demonstrate that TRAIL expression is strongly inhibited in DCs after CD40 engagement. In contrast, TNF-{alpha} was strongly induced by CD40L but not IFN-{alpha} or dsRNA (Fig. 5GoC). This effect was exclusively dependent on CD40 engagement as neutralizing anti-CD40L Abs blocked TNF-{alpha} induction. Control L cells did not induce TNF-{alpha} expression. Thus, CD40L ensures a switch in TNF-related family members expressed in DCs since TRAIL is inhibited but TNF-{alpha} induced after CD40 engagement.



View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 5. TRAIL inhibition and TNF-{alpha} induction after CD40 engagement in DCs. A, DCs were stimulated with dsRNA (0.2 µg/ml) or IFN-{alpha} (5000 U/ml) for 16 h. Untransfected L cells or CD40L+ L cells were added as precised. FasL and TRAIL mRNA expression was quantified by performing an RNase protection assay (RiboQuant hApo3c; BD PharMingen) on total RNA extracts. L32 mRNA, encoding a constitutively expressed ribosomal protein, was used as a control probe. B and C, DCs were stimulated with dsRNA (0.2 µg/ml) or IFN-{alpha} (5000 U/ml) for 16 h in the presence of control L cells or CD40L+ L cells. Neutralizing anti-CD40L Ab (LL2, 10 µg/ml) was eventually added to the coculture of CD40L+ L cells and DCs. TRAIL (B) and TNF-{alpha} (C) expression in DCs was determined by flow cytometry analysis. Results presented are one representative experiment of five.

 
CD40-activated DCs are cytotoxic via TNF-{alpha} and a yet unidentified pathway

To check whether CD40-activated DCs developed cytotoxic activity, DCs were cultured for 16 h in the presence of CD40L+ L cells, then cytotoxicity against TNF-{alpha}-sensitive MDA231 cells was tested. As shown in Fig. 6Go, CD40-activated DCs induced MDA231 cell lysis. Since CD40-activated DCs express neither TRAIL nor FasL but high levels of TNF-{alpha}, its contribution to DC cytotoxicity was examined. Anti-TWEAK/Apo3L-neutralizing Abs had no effect on MDA231 lysis. In contrast, anti-TNF-{alpha}-neutralizing Abs exhibited a weak but significant inhibitory effect on the cytotoxicity of CD40-stimulated DCs (Fig. 6Go). Remaining DC cytotoxicity could not be blocked even with the highest dose (20 µg/ml) of anti-TNF-{alpha} Ab. Yet, anti-TNF-{alpha} Ab at 10 µg/ml was sufficient to abrogate optimal MDA231 lysis induced by rTNF-{alpha} at 30 ng/ml (data not shown). Thus, CD40-activated DCs are cytotoxic via TNF-{alpha} but also a yet unidentified TRAIL/FasL/TWEAK-independent pathway.



View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 6. Cytotoxicity of CD40L-stimulated DCs. DCs were stimulated with CD40L+ L cells or control L cells for 16 h. Cytotoxicity was then tested against MDA231 cells by an 8-h 51Cr release assay at different E:T ratios. Neutralizing anti-TNF-{alpha} or anti-TWEAK/Apo3L (CARL-1) was added or not in the assay to inhibit TNF-{alpha}- or TWEAK/Apo3L-induced lysis. Data represent the mean of triplicate samples (SD below 5%). Results presented are one representative experiment of five.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
According to literature, the major function of DCs is to process and present Ags to activate specific T lymphocytes and trigger adaptative immune response. However, beside their APC function, DCs were described to exert a cytotoxic activity. In mice, DC cytotoxicity was reported in the two major DC subpopulations described as "myeloid-related" (CD11bhighCD8{alpha}-) and "lymphoid-related" (CD11blowCD8{alpha}+) DCs. A subset of lymphoid-related splenic DCs has been shown to mediate apoptosis of CD4+ T cells (38). Lu et al. (39) also found that murine bone marrow-derived DCs express FasL and could induce apoptosis in Jurkat T cells. In rat, cytolytic DCs were characterized by their CD4-OX41-CD5- phenotype and their capacity to induce tumor cell apoptosis by a FasL-, TRAIL-, and TNF-{alpha}-independent pathway (40, 41). Recently, a subset of myeloid-related human blood DCs was characterized by its cytotoxicity toward several tumor cell lines through the expression of TRAIL (10). However, this human DC subset needs to be activated by IFN-{gamma} or IFN-{alpha} to express TRAIL and acquire the ability to kill. Finally, IFN-{beta} and measles virus (MV) infection were reported to induce functional TRAIL expression in human monocyte-derived DCs (11, 12). In this report, we demonstrate that dsRNA poly(I:C) and CD40L, that were previously characterized as maturation signals, are also potent stimulators of DC cytotoxicity. dsRNA-induced cytotoxicity is shown to be mediated by TRAIL, this latter being induced in DCs by an autocrine IFN-{beta} loop. Contrary to dsRNA, we document that CD40L acts as an inhibitor of TRAIL expression but induces TNF-{alpha} synthesis and unidentified factor(s) that both mediate the presently reported cytotoxicity of CD40L-stimulated DCs.

Poly(I:C) is a synthetic dsRNA often used in models of viral infections. Indeed, dsRNA is considered as a structural signature of the viral replication cycle which plays a critical role in the induction of antiviral type I IFNs (31). It has been proposed that recognition of conserved molecular patterns (PAMPs) that are characteristic of pathogens is a property of the innate immune system (2). We clearly confirm that dsRNA behaves as a PAMP that can directly signal to DCs, inducing maturation as previously described (32, 33, 34). Furthermore, a newly documented function is attributed to dsRNA in the present report: the induction of TRAIL-mediated DC cytotoxicity. TRAIL is a TNF family member characterized as a potent and specific inducer of tumoral cell apoptosis (13, 14, 25, 26, 27). As reported here, poly(I:C)-treated DCs exhibit TRAIL-mediated tumoricidal activity in vitro. Interestingly, TRAIL induction by poly(I:C) is probably not restricted to DCs since a significant induction of TRAIL has been reported in T lymphocytes (42) and monocytes (Fig. 2GoA). Interestingly, our data show that TRAIL is highly expressed on the cell surface of monocytes, but is mainly cytoplasmic in DCs. This is in agreement with the Fanger et al. (10, 43) report where surface TRAIL expression is shown to be bright in IFN-{gamma}-stimulated monocytes but weak in IFN-{gamma}-stimulated blood-derived CD11c+ DCs. These results suggest that in DCs but not in monocytes, TRAIL is cleaved on the cell surface by a specific protease. Finally, TRAIL induction by poly(I:C) is shown to be dependent on IFN-{beta} production in DCs, in agreement with Liu et al. (11) who reported the induction of a TRAIL-mediated tumoricidal activity in monocyte-derived DCs treated with rIFN-{beta}. More than 20 years ago, poly(I:C) was reported to stimulate macrophage tumoricidal activity (44) and to induce tumor regression in vivo (45, 46) through unidentified mechanisms. Our data suggest that TRAIL induction by poly(I:C) may partly account for the antitumoral activity of this molecule.

Beside their potential antitumoral activity in vivo, TRAIL-expressing DCs could also participate in innate antiviral immunity. Indeed, TRAIL may have a pivotal function in antiviral immune responses since virus-infected cells are sensitized to TRAIL-induced apoptosis by as yet unidentified mechanisms (23, 24). On the basis of our results, dsRNA synthesized during the viral replication cycle might signal to DCs and induce TRAIL expression. In this context, TRAIL-expressing DCs could act in vivo as innate immunity effector cells inducing virus-infected cell lysis. Because DCs reside in peripheral tissues, they might constitute a first and essential barrier against incoming viruses. Several recent reports also suggest that TRAIL participates in the establishment of MV- and HIV-induced immunosuppression. We reported that MV-infected DCs express TRAIL and induce MV-uninfected T cell apoptosis (12, 35). Increased sensitivity of T cells from HIV patients to TRAIL-induced apoptosis has been reported (25, 47). In a PBL-nonobese diabetic-SCID mouse model, a large number of HIV-uninfected CD4+ T cells undergo TRAIL-mediated apoptosis in HIV-infected lymphoid organs (48). Since dsRNA is produced during MV and HIV replication cycles, this molecule could induce massive TRAIL expression in DCs during viral spreading. Such overexpression of TRAIL may participate in T cell deletion, lymphopenia, and establishment of virus-induced immunosuppression.

Recently, TRAIL was also characterized in mice as a negative regulator of adaptative immune response through the inhibition of T cell proliferation and cytokine production (29, 30). Moreover, TRAIL was described as a weak inducer of normal T cell apoptosis (49). In this work, we newly report the inhibition of TRAIL in DCs after CD40 engagement. Inhibition of TRAIL mRNA after CD40 ligation was reported in follicular lymphoma and normal B cells (50). Interestingly, among CD40L-induced factors in DCs is osteoprotegerin that is a soluble decoy receptor for TRAIL (51). Thus, CD40L-mediated inhibition of the TRAIL pathway in DCs could be mediated, not only through TRAIL down-regulation, but also by osteoprotegerin induction. Contrary to TRAIL, TNF-{alpha} is induced in DCs by CD40L and was reported to promote resting T cell proliferation through TNFR2 engagement (52). Altogether, these results suggest that CD40 engagement ensures optimal Ag presentation by DCs, not only through the induction of MHC molecules and costimulatory factors for T cells such as TNF-{alpha}, but also through the inhibition of the TRAIL pathway. In addition, CD40 ligation was recently described to ablate the tolerogenic potential of CD8+ DCs in mice (53). This could be explained by CD40-mediated inhibition of TRAIL or any other TRAIL-related factor as CD8+ DCs were reported to exert a cytotoxic activity toward CD4+ T cells (38).

Finally, we demonstrate for the first time that CD40-activated DCs can develop cytotoxic activity. It is unlikely that FasL or TRAIL mediate cytotoxicity since they are not expressed in CD40-activated DCs. Cytotoxic activity of CD40-activated DCs is also shown to be TWEAK/Apo3L independent. In contrast, we demonstrate that the TNF-{alpha} contribution to cytotoxicity is weak but significant. Thus, cytotoxicity of CD40-activated DCs is partly dependent on TNF-{alpha} but mainly mediated via a yet unidentified pathway. Whatever the contribution of TNF-{alpha}, these results document the fact that even fully mature CD40L-activated DCs can develop cytotoxic activity.

In vivo function of cytotoxic DCs is not yet defined, but several hypothesis have been formulated. They could be tolerogenic cells that induce apoptosis of autoreactive lymphocytes. They could act as regulators of immune responses that limit specific lymphocyte expansion. They could be also considered as innate immunity effector cells with a NK-like activity. In this report, we demonstrate that dsRNA- and CD40L-treated DCs develop tumoricidal activity that is mediated through two different pathways. In vivo relevance of such tumoricidal activity has to be demonstrated. Moreover, it would be of great interest to test whether the killing of target cells by DCs is followed by phagocytosis of their victims and efficient cross-presentation of target cell-derived Ags to T cells (54, 55). Cytotoxic DCs would therefore create an immediate link between innate and adaptive immunity that should not be ignored for DC-based immunotherapy.


   Acknowledgments
 
We thank Dr. Fabian Wild and Adrienne Anginot for their helpful technical participation in this work.


   Footnotes
 
1 This work was supported by Institut National de la Santé et de la Recherche Médicale, Association pour la Recherche sur le Cancer (Cancer Research Campaign Grant 5753), Région-Rhône-Alpes Emergence HMCO3F, and Agence Nationale de Recherches sur le SIDA (FF049G). Back

2 Address correspondence and reprint requests to Dr. Christine Servet-Delprat, Laboratoire d’Immunobiologie Fondamentale et Clinique, Institut National de la Santé et de la Recherche Médicale Unité 503, 21 Avenue Tony Garnier, 69365 Lyon, Cedex 07, France. E-mail address: servet{at}cervi-lyon.inserm.fr Back

3 Abbreviations used in this paper: DC, dendritic cell; CD40L, CD40 ligand; FasL, Fas ligand; PAMP, pathogen-associated molecular pattern; TRAIL, TNF-related apoptosis-inducing ligand; rh, recombinant human; MV, measles virus. Back

Received for publication April 27, 2001. Accepted for publication July 31, 2001.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Banchereau, J., R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.[Medline]
  2. Medzhitov, R., C. A. Janeway. 1997. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91:295.[Medline]
  3. Sallusto, F., M. Cella, C. Danieli, A. Lanzavecchia. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182:389.[Abstract/Free Full Text]
  4. Sparwasser, T., E. S. Koch, R. M. Vabulas, K. Heeg, G. B. Lipford, J. W. Ellwart, H. Wagner. 1998. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol. 28:2045.[Medline]
  5. Roy, M., T. Waldschmidt, A. Aruffo, J. A. Ledbetter, R. J. Noelle. 1993. The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J. Immunol. 151:2497.[Abstract]
  6. Cella, M., D. Scheidegger, K. Palmer-Lehmann, P. Lane, A. Lanzavecchia, G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747.[Abstract/Free Full Text]
  7. Ridge, J. P., F. Di Rosa, P. Matzinger. 1998. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474.[Medline]
  8. Caux, C., C. Massacrier, B. Vanbervliet, B. Dubois, C. Van Kooten, I. Durand, J. Banchereau. 1994. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180:1263.[Abstract/Free Full Text]
  9. Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufler, E. Kampgen, N. Romani, G. Schuler. 1996. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 184:741.[Abstract/Free Full Text]
  10. Fanger, N. A., C. R. Maliszewski, K. Schooley, T. S. Griffith. 1999. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Exp. Med. 190:1155.[Abstract/Free Full Text]
  11. Liu, S., Y. Yu, M. Zhang, W. Wang, X. Cao. 2001. The involvement of TNF-{alpha}-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-{beta}-stimulated human dendritic cells to tumor cells. J. Immunol. 166:5407.[Abstract/Free Full Text]
  12. Vidalain, P. O., O. Azocar, B. Lamouille, A. Astier, C. Rabourdin-Combe, C. Servet-Delprat. 2000. Measles virus induces functional TRAIL production by human dendritic cells. J. Virol. 74:556.[Abstract/Free Full Text]
  13. Wiley, S. R., K. Schooley, P. J. Smolak, W. S. Din, C. P. Huang, J. K. Nicholl, G. R. Sutherland, T. D. Smith, C. Rauch, C. A. Smith. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673.[Medline]
  14. Pitti, R. M., S. A. Marsters, S. Ruppert, C. J. Donahue, A. Moore, A. Ashkenazi. 1996. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271:12687.[Abstract/Free Full Text]
  15. Pan, G., K. O’Rourke, A. M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni, V. M. Dixit. 1997. The receptor for the cytotoxic ligand TRAIL. Science 276:111.[Abstract/Free Full Text]
  16. Pan, G., J. Ni, Y. F. Wei, G. Yu, R. Gentz, V. M. Dixit. 1997. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815.[Abstract/Free Full Text]
  17. Sheridan, J. P., S. A. Marsters, R. M. Pitti, A. Gurney, M. Skubatch, D. Baldwin, L. Ramakrishnan, C. L. Gray, K. Baker, W. I. Wood, et al 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818.[Abstract/Free Full Text]
  18. Screaton, G. R., J. Mongkolsapaya, X. N. Xu, A. E. Cowper, A. J. McMichael, J. I. Bell. 1997. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr. Biol. 7:693.[Medline]
  19. Walczak, H., M. A. Degli-Esposti, R. S. Johnson, P. J. Smolak, J. Y. Waugh, N. Boiani, M. S. Timour, M. J. Gerhart, K. A. Schooley, C. A. Smith, et al 1997. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16:5386.[Medline]
  20. Wu, G. S., T. F. Burns, E. R. McDonald, W. Jiang, R. Meng, I. D. Krantz, G. Kao, D. D. Gan, J. Y. Zhou, R. Muschel, et al 1997. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17:141.[Medline]
  21. Kischkel, F. C., D. A. Lawrence, A. Chuntharapai, P. Schow, K. J. Kim, A. Ashkenazi. 2000. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12:611.[Medline]
  22. Sprick, M. R., M. A. Weigand, E. Rieser, C. T. Rauch, P. Juo, J. Blenis, P. H. Krammer, H. Walczak. 2000. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12:599.[Medline]
  23. Sedger, L. M., D. M. Shows, R. A. Blanton, J. J. Peschon, R. G. Goodwin, D. Cosman, S. R. Wiley. 1999. IFN-{gamma} mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J. Immunol. 163:920.[Abstract/Free Full Text]
  24. Clarke, P., S. M. Meintzer, S. Gibson, C. Widmann, T. P. Garrington, G. L. Johnson, K. L. Tyler. 2000. Reovirus-induced apoptosis is mediated by TRAIL. J. Virol. 74:8135.[Abstract/Free Full Text]
  25. Jeremias, I., I. Herr, T. Boehler, K. M. Debatin. 1998. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur. J. Immunol. 28:143.[Medline]
  26. Griffith, T. S., W. A. Chin, G. C. Jackson, D. H. Lynch, M. Z. Kubin. 1998. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161:2833.[Abstract/Free Full Text]
  27. Mariani, S. M., B. Matiba, E. A. Armandola, P. H. Krammer. 1997. Interleukin 1{beta}-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J. Cell Biol. 137:221.[Abstract/Free Full Text]
  28. Walczak, H., R. E. Miller, K. Ariail, B. Gliniak, T. S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, et al 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5:157.[Medline]
  29. Song, K., Y. Chen, R. Goke, A. Wilmen, C. Seidel, A. Goke, B. Hilliard. 2000. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J. Exp. Med. 191:1095.[Abstract/Free Full Text]
  30. Hilliard, B., A. Wilmen, C. Seidel, T. S. Liu, R. Goke, Y. Chen. 2001. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J. Immunol. 166:1314.[Abstract/Free Full Text]
  31. Jacobs, B. L., J. O. Langland. 1996. When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Virology 219:339.[Medline]
  32. Cella, M., M. Salio, Y. Sakakibara, H. Langen, I. Julkunen, A. Lanzavecchia. 1999. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J. Exp. Med. 189:821.[Abstract/Free Full Text]
  33. Verdijk, R. M., T. Mutis, B. Esendam, J. Kamp, C. J. Melief, A. Brand, E. Goulmy. 1999. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J. Immunol. 163:57.[Abstract/Free Full Text]
  34. Kadowaki, N., S. Antonenko, Y. J. Liu. 2001. Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J. Immunol. 166:2291.[Abstract/Free Full Text]
  35. Fugier-Vivier, I., C. Servet-Delprat, P. Rivailler, M. C. Rissoan, Y. J. Liu, C. Rabourdin-Combe. 1997. Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells. J. Exp. Med. 186:813.[Abstract/Free Full Text]
  36. Kayagaki, N., N. Yamaguchi, M. Nakayama, A. Kawasaki, H. Akiba, K. Okumura, H. Yagita. 1999. Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J. Immunol. 162:2639.[Abstract/Free Full Text]
  37. Nakayama, M., N. Kayagaki, N. Yamaguchi, K. Okumura, H. Yagita. 2000. Involvement of TWEAK in interferon {gamma}-stimulated monocyte cytotoxicity. J. Exp. Med. 192:1373.[Abstract/Free Full Text]
  38. Suss, G., K. Shortman. 1996. A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J. Exp. Med. 183:1789.[Abstract/Free Full Text]
  39. Lu, L., S. Qian, P. A. Hershberger, W. A. Rudert, D. H. Lynch, A. W. Thomson. 1997. Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J. Immunol. 158:5676.[Abstract]
  40. Josien, R., M. Heslan, J. P. Soulillou, M. C. Cuturi. 1997. Rat spleen dendritic cells express natural killer cell receptor protein 1 (NKR-P1) and have cytotoxic activity to select targets via a Ca2+-dependent mechanism. J. Exp. Med. 186:467.[Abstract/Free Full Text]
  41. Trinite, B., C. Voisine, H. Yagita, R. Josien. 2000. A subset of cytolytic dendritic cells in rat. J. Immunol. 165:4202.[Abstract/Free Full Text]
  42. Kayagaki, N., N. Yamaguchi, M. Nakayama, H. Eto, K. Okumura, H. Yagita. 1999. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189:1451.[Abstract/Free Full Text]
  43. Griffith, T. S., S. R. Wiley, M. Z. Kubin, L. M. Sedger, C. R. Maliszewski, N. A. Fanger. 1999. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 189:1343.[Abstract/Free Full Text]
  44. Alexander, P., R. Evans. 1971. Endotoxin and double stranded RNA render macrophages cytotoxic. Nat. New Biol. 232:76.[Medline]
  45. Pimm, M. V., M. J. Embleton, R. W. Baldwin. 1976. Treatment of transplanted rat tumours with double-stranded RNA (BRL 5907). I. Influenced of systemic and local administration. Br. J. Cancer 33:154.[Medline]
  46. Pimm, M. V., R. W. Baldwin. 1976. Treatment of transplanted rat tumours with double-stranded RNA(BRL 5907). II. Treatment of pleural and peritoneal growths. Br. J. Cancer 33:166.[Medline]
  47. Katsikis, P. D., M. E. Garcia-Ojeda, J. F. Torres-Roca, I. M. Tijoe, C. A. Smith, L. A. Herzenberg, M. MacFarlane, M. Ahmad, S. M. Srinivasula, T. Fernandes-Alnemri, et al 1997. Interleukin-1{beta} converting enzyme-like protease involvement in Fas-induced and activation-induced peripheral blood T cell apoptosis in HIV infection: TNF-related apoptosis-inducing ligand can mediate activation-induced T cell death in HIV infection. J. Exp. Med. 186:1365.[Abstract/Free Full Text]
  48. Miura, Y., N. Misawa, N. Maeda, Y. Inagaki, Y. Tanaka, M. Ito, N. Kayagaki, N. Yamamoto, H. Yagita, H. Mizusawa, Y. Koyanagi. 2001. Critical contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to apoptosis of human CD4+ T cells in HIV-1-infected hu-PBL-NOD-SCID mice. J. Exp. Med. 193:651.[Abstract/Free Full Text]
  49. Marsters, S. A., R. M. Pitti, C. J. Donahue, S. Ruppert, K. D. Bauer, A. Ashkenazi. 1996. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr. Biol. 6:750.[Medline]
  50. Ribeiro, P., N. Renard, K. Warzocha, C. Charlot, L. Jeandenant, E. Callet-Bauchu, B. Coiffier, G. Salles. 1998. CD40 regulation of death domains containing receptors and their ligands on lymphoma B cells. Br. J. Haematol. 103:684.[Medline]
  51. Yun, T. J., P. M. Chaudhary, G. L. Shu, J. K. Frazer, M. K. Ewings, S. M. Schwartz, V. Pascual, L. E. Hood, E. A. Clark. 1998. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J. Immunol. 161:6113.[Abstract/Free Full Text]
  52. Tartaglia, L. A., D. V. Goeddel, C. Reynolds, I. S. Figari, R. F. Weber, B. M. Fendly, M. A. Palladino. 1993. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J. Immunol. 151:4637.[Abstract]
  53. Grohmann, U., F. Fallarino, S. Silla, R. Bianchi, M. L. Belladonna, C. Vacca, A. Micheletti, M. C. Fioretti, P. Puccetti. 2001. CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. J. Immunol. 166:277.[Abstract/Free Full Text]
  54. Inaba, K., S. Turley, F. Yamaide, T. Iyoda, K. Mahnke, M. Inaba, M. Pack, M. Subklewe, B. Sauter, D. Sheff, et al 1998. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J. Exp. Med. 188:2163.[Abstract/Free Full Text]
  55. Albert, M. L., B. Sauter, N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86.[Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
K. S. Hill, F. Errington, L. P. Steele, A. Merrick, R. Morgan, P. J. Selby, N. T. Georgopoulos, D. M. O'Donnell, and A. A. Melcher
OK432-Activated Human Dendritic Cells Kill Tumor Cells via CD40/CD40 Ligand Interactions
J. Immunol., September 1, 2008; 181(5): 3108 - 3115.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Chauvin and R. Josien
Dendritic Cells as Killers: Mechanistic Aspects and Potential Roles
J. Immunol., July 1, 2008; 181(1): 11 - 16.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
F. Herschke, S. Plumet, T. Duhen, O. Azocar, J. Druelle, D. Laine, T. F. Wild, C. Rabourdin-Combe, D. Gerlier, and H. Valentin
Cell-Cell Fusion Induced by Measles Virus Amplifies the Type I Interferon Response
J. Virol., December 1, 2007; 81(23): 12859 - 12871.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. M. Lundberg, S. K. Drexler, C. Monaco, L. M. Williams, S. M. Sacre, M. Feldmann, and B. M. Foxwell
Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems
Blood, November 1, 2007; 110(9): 3245 - 3252.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
Z. Wang, L. Xiang, J. Shao, and Z. Yuan
The 3' CCACCA Sequence of tRNAAla(UGC) Is the Motif That Is Important in Inducing Th1-Like Immune Response, and This Motif Can Be Recognized by Toll-Like Receptor 3.
Clin. Vaccine Immunol., July 1, 2006; 13(7): 733 - 739.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. Trinite, C. Chauvin, H. Peche, C. Voisine, M. Heslan, and R. Josien
Immature CD4-CD103+ Rat Dendritic Cells Induce Rapid Caspase-Independent Apoptosis-Like Cell Death in Various Tumor and Nontumor Cells and Phagocytose Their Victims
J. Immunol., August 15, 2005; 175(4): 2408 - 2417.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
I. M. Klagge, M. Abt, B. Fries, and S. Schneider-Schaulies
Impact of measles virus dendritic-cell infection on Th-cell polarization in vitro
J. Gen. Virol., November 1, 2004; 85(11): 3239 - 3247.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
W. J. Kaiser, J. L. Kaufman, and M. K. Offermann
IFN-{alpha} Sensitizes Human Umbilical Vein Endothelial Cells to Apoptosis Induced by Double-Stranded RNA
J. Immunol., February 1, 2004; 172(3): 1699 - 1710.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
R. Greil, G. Anether, K. Johrer, and I. Tinhofer
Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools
J. Leukoc. Biol., September 1, 2003; 74(3): 311 - 330.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
S.M. Santini, T. Di Pucchio, C. Lapenta, S. Parlato, M. Logozzi, and F. Belardelli
A New Type I IFN-Mediated Pathway for the Rapid Differentiation of Monocytes into Highly Active Dendritic Cells
Stem Cells, May 1, 2003; 21(3): 357 - 362.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Voisine, F.-X. Hubert, B. Trinite, M. Heslan, and R. Josien
Two Phenotypically Distinct Subsets of Spleen Dendritic Cells in Rats Exhibit Different Cytokine Production and T Cell Stimulatory Activity
J. Immunol., September 1, 2002; 169(5): 2284 - 2291.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vidalain, P.-O.
Right arrow Articles by Servet-Delprat, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vidalain, P.-O.
Right arrow Articles by Servet-Delprat, C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS